STN-structure search 1-24-04

=> d ibib abs hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:633448 CAPLUS
DOCUMENT NUMBER: 139:185666
TITLE: Coated pharmaceutical tablets with speckled appearance
INVENTOR(S): Martino, Alice C.; Noack, Robert M.; Pierman, Steven A.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066030	A2	20030814	WO 2003-US3837	20030206
WO 2003066030	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003180357	A1	20030925	US 2003-359939	20030206

PRIORITY APPLN. INFO.: US 2002-355705P P 20020207
OTHER SOURCE(S): MARPAT 139:185666

AB A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-sol. dye distributed in a matrix and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

IT **282522-93-4 282522-94-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated pharmaceutical tablets with speckled appearance)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-,

(5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:633447 CAPLUS
DOCUMENT NUMBER: 139:185665
TITLE: Pharmaceutical dosage form for mucosal delivery
INVENTOR(S): Martino, Alice C.; Pierman, Steven A.; Noack, Robert M.; Britten, Nancy
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066029	A2	20030814	WO 2003-US3836	20030206
WO 2003066029	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,

ML, MR, NE, SN, TD, TG
US 2003235617 A1 20031225 US 2003-360167 20030206
PRIORITY APPLN. INFO.: US 2002-355703P P 20020207

AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.

IT **282522-93-4 282522-94-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated sublingual tablets)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:22671 CAPLUS
DOCUMENT NUMBER: 138:78475
TITLE: Enhanced pharmacokinetic profile of hydrophobic dopamine agonists administered to the dermis
INVENTOR(S): Pinkerton, Thomas C.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002103	A2	20030109	WO 2002-US19918	20020624
WO 2003002103	A3	20030410		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003073609	A1	20030417	US 2001-897801	20010629

PRIORITY APPLN. INFO.: US 2001-897801 A2 20010629
OTHER SOURCE(S): MARPAT 138:78475

AB A method for systemic administration of a hydrophobic dopamine agonist to a mammal is disclosed. The method involves delivering the hydrophobic dopamine agonist to the dermis of the mammal, whereby improved systemic absorption is obtained compared to absorption produced upon delivering the substance s.c. by bolus administration.

IT **282522-93-4**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetic profile enhancement of hydrophobic dopamine agonist delivered to dermis)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:22662 CAPLUS

DOCUMENT NUMBER: 138:78468
TITLE: Enhanced pharmacokinetic profile of hydrophobic substances delivered to the dermis
INVENTOR(S): Pinkerton, Thomas C.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002094	A2	20030109	WO 2002-US20080	20020624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003073609	A1	20030417	US 2001-897801	20010629

PRIORITY APPLN. INFO.: US 2001-897801 A2 20010629

AB A method for systemic administration of a hydrophobic substance to a mammal is disclosed. The method involves delivering the hydrophobic substance to the dermis of the mammal whereby improved systemic absorption is obtained compared to absorption produced upon delivering the substance s.c. by bolus administration.

IT **282522-93-4**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetic profile enhancement of hydrophobic substance delivered to dermis)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:615377 CAPLUS
DOCUMENT NUMBER: 137:174924
TITLE: Rapid-onset medicament for the treatment of sexual dysfunction
INVENTOR(S): Martino, Alice C.; McCurdy, Vincent E.; Pierman, Steven A.; Reo, Joseph P.; Tyle, Praveen; Wu, Sy Juen
PATENT ASSIGNEE(S): Pharmacia Corporation, USA

10/634,355

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062315	A1	20020815	WO 2002-US3680	20020207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003022912	A1	20030130	US 2002-72368	20020207
EP 1365740	A1	20031203	EP 2002-709405	20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003003508	A	20031001	NO 2003-3508	20030807

PRIORITY APPLN. INFO.:
US 2001-267519P P 20010208
WO 2002-US3680 W 20020207

OTHER SOURCE(S): MARPAT 137:174924
GI



I

AB A rapid-onset pharmaceutical compn. is provided, useful for treatment of sexual dysfunction, stimulation of sexual activity and enhancement of sexual desire, interest and performance in men and women. The compn. is a dosage form comprising (a) a therapeutically or sexual-stimulatorily effective amt. of a therapeutic agent having a mol. wt., excluding counterions, not greater than 250, and (b) at least one pharmaceutically acceptable excipient; and is adapted for delivery by a route of administration that entails interaction with the organs of taste yet has acceptable organoleptic properties. Illustrative therapeutic agents useful in dosage forms of the invention are I or its maleate salt.

IT **282522-93-4**, 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- **282522-94-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapid-onset medicament for the treatment of sexual dysfunction)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:353281 CAPLUS
DOCUMENT NUMBER: 136:355238
TITLE: Preparation of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome
INVENTOR(S): McBrinn, Sylvia; Anderson, Richard W.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036123	A2	20020510	WO 2001-US27785	20011029
WO 2002036123	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002011226	A5	20020515	AU 2002-11226	20011029
US 2002107257	A1	20020808	US 2001-39446	20011029
US 6602868	B2	20030805		
BR 2001015071	A	20030729	BR 2001-15071	20011029
EP 1330248	A2	20030730	EP 2001-979241	20011029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003212065	A1	20031113	US 2003-423078	20030425
NO 2003001923	A	20030627	NO 2003-1923	20030429
PRIORITY APPLN. INFO.:			US 2000-244666P	P 20001031
			US 2001-39446	A3 20011029
			WO 2001-US27785	W 20011029

OTHER SOURCE(S): MARPAT 136:355238
GI



I



II



III



IV

AB Invention compds. I and II [R1-3 = H, alk(en/yn)yl, cycloalkyl, cycloalkyl or R1-2 are joined to form a cyclic amine; X = H, alkyl, halo, hydroxy, alkoxy, cyano, carboxamide, carboxy, carboalkoxyl; A = CH, CH2, CH-halo, CHCH3, C=O, C=S, C-SCH3, C=NH, C-NH2, C-NHCH3, C-NHCOOCH3, C-NHCN, SO2, N; B = CH2, CH, CH-halo, C=O, N, NH, N-CH3; n = 0-1; D = CH, CH2, CH-halo, C=O, O, N, NH, N-CH3; p = 0-3; R4-5 = H (provided only one is H at the same time), OH (provided R7 is other than hydrogen), CN, CH2CN, 2- or 4-CF3, CH2CF3, CH2CHF2, CH=CF2, (CH2)2CF3, ethenyl, 2-propenyl, OSO2CH3, OSO2CF3, SSO2CF3, COR7, COOR7, CON(R7)2, SO0-2CH3, SO0-2CF3, etc.; R6 = H, CF3, CH2CF3, alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, etc.; R7 = H, CF3, CH2CF3, alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl,etc.] were prepd. For instance, (R)-Naproxen chloride (prepn. given) was coupled to 1-Benzyl-5-bromo-6-hydroxy-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (prepn. given) and the resulting ester treated with MeNH2 in CH3CN to afford intermediate amino alc. III. III was converted to the aziridine via the benzenesulfonate and subsequently treated with Li/NH3 to effect debenzylation and aziridine ring opening. The resulting amide was converted to thioamide IV (pyridine, P4S10, 125.degree.C, 5 h). I and II are useful for treating restless leg syndrome (RLS).

IT **282522-93-4P 282522-94-5P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; prepn. of imidazoquinolines and phenylazacycloalkanes as treatments for restless legs syndrome)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:142501 CAPLUS
DOCUMENT NUMBER: 136:205395
TITLE: Compounds for the treatment of addictive disorders
INVENTOR(S): Anderson, Richard W.; McBrinn, Sylvia S.; Robertson, David W.; Marshall, Robert C.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013807	A2	20020221	WO 2001-US25603	20010813
WO 2002013807	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001083393	A5	20020225	AU 2001-83393	20010813
EP 1363634	A2	20031126	EP 2001-962196	20010813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002049206	A1	20020425	US 2001-929666	20010814
US 2003078273	A1	20030424	US 2002-295331	20021115
NO 2003000717	A	20030214	NO 2003-717	20030214
PRIORITY APPLN. INFO.:			US 2000-225714P	P 20000816
			US 2001-263610P	P 20010123

WO 2001-US25603 W 20010813
US 2001-929666 A3 20010814

OTHER SOURCE(S): MARPAT 136:205395

GI



I



II

AB The treatment of addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alc. addiction, tobacco addiction, and nicotine addiction using a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an arom. bicyclic amine active agent, or a pharmaceutically acceptable deriv. or salt of any said active agent is described. Example compds. are I and II.

IT **282522-93-4 282522-94-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. for the treatment of addictive disorders)

RN 282522-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4

CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



give refs

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:816667 CAPLUS
DOCUMENT NUMBER: 135:344486
TITLE: (5R)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1H)-thione
INVENTOR(S): Acker, Brad A.; Heier, Richard F.; Jin, Alan Q.; Moon, Malcolm W.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083483	A1	20011108	WO 2001-US10814	20010419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002137763	A1	20020926	US 2001-838054	20010419
BR 2001010323	A	20030107	BR 2001-10323	20010419
JP 2003531907	T2	20031028	JP 2001-580911	20010419

PRIORITY APPLN. INFO.:
US 2000-199954P P 20000427
US 2000-234101P P 20000921
WO 2001-US10814 W 20010419

OTHER SOURCE(S): MARPAT 135:344486

AB (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and its pharmaceutically acceptable salts were prepd. from 4H-imidazo[4,5,1-ij]quinolin-2(1H)-one in 7 steps via N-benzylation, bromohydroxylation, resoln. with (R)-Naproxen, aminolysis with MeNH2, dehydration, acid hydrolysis of the resulting aziridine ring, reaction with Lawesson's reagent, and salt formation.

IT **282522-93-4P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (5R)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1H)-thione)

RN 282522-93-4 CAPLUS

CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **282522-94-5P 371163-17-6P 371163-18-7P**
371163-19-8P 371163-20-1P 371163-21-2P
371163-22-3P 371163-23-4P 371163-24-5P
371163-25-6P 371163-26-7P 371163-27-8P
371163-28-9P 371163-29-0P 371163-30-3P
371163-31-4P 371163-32-5P 371163-33-6P
371163-34-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of (5R)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1H)-thione)

RN 282522-94-5 CAPLUS

CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 371163-17-6 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 371163-18-7 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, monohydrobromide, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HBr

RN 371163-19-8 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 371163-20-1 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 371163-21-2 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-,

(5R)-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3



RN 371163-22-3 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 371163-23-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 371163-24-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 371163-25-6 CAPLUS
CN Propanoic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 79-09-4
CMF C3 H6 O2



RN 371163-26-7 CAPLUS
CN Butanoic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 107-92-6
CMF C4 H8 O2



RN 371163-27-8 CAPLUS
CN Pentanoic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 109-52-4
CMF C5 H10 O2



RN 371163-28-9 CAPLUS
CN Hexanoic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-

imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 142-62-1
CMF C6 H12 O2



RN 371163-29-0 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 371163-30-3 CAPLUS
CN Propanedioic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 141-82-2
CMF C3 H4 O4



RN 371163-31-4 CAPLUS
CN Butanedioic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 371163-32-5 CAPLUS
CN Pentanedioic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-94-1
CMF C5 H8 O4

$HO_2C-(CH_2)_3-CO_2H$

RN 371163-33-6 CAPLUS
CN Hexanedioic acid, compd. with (5R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 124-04-9
CMF C6 H10 O4

$HO_2C-(CH_2)_4-CO_2H$

RN 371163-34-7 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 65-85-0
CMF C7 H6 O2



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:798221 CAPLUS
DOCUMENT NUMBER: 135:331428
TITLE: Preparation of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome.
INVENTOR(S): McCall, Robert B.; Marshall, Robert C.; Robertson, David W.; Ashley, Thomas M.
PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081343	A2	20011101	WO 2001-US10807	20010417
WO 2001081343	A3	20020228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,

RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002004510	A1	20020110	US 2001-836660	20010417
US 6448258	B2	20020910		
EP 1274430	A2	20030115	EP 2001-926590	20010417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010210	A	20030128	BR 2001-10210	20010417
US 2002143010	A1	20021003	US 2002-159913	20020530
US 6555548	B2	20030429		
US 2003191149	A1	20031009	US 2003-383467	20030307

PRIORITY APPLN. INFO.:

US 2000-198959P	P	20000421
US 2000-200569P	P	20000428
US 2001-836660	A3	20010417
WO 2001-US10807	W	20010417
US 2002-159913	A3	20020530

OTHER SOURCE(S): MARPAT 135:331428

GI



I

AB Use of title compds., e.g., (I; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, phenylalkyl; R1R2N = cyclic amine; X = H, alkyl, halo, OH, alkoxy, cyano, carboxamide, CO2H, carboalkoxy; A = CH, CH2, CHY, CHMe, CO, CS, CSMe, CNH2, SO2, N, etc.; B = null, CH2, CH, CHY, CO, N, NH, NMe, O; D = CH, CH2, CHY, CO, O, N, NH, NMe; Y = halo) for prepn. of medicaments for the treatment of symptoms of fibromyalgia or chronic fatigue syndrome is claimed (no data). Thus, 4H-imidazo[4,5,1-ij]quinolin-2(1H)-one was converted in several steps to (5R)-5-methylamino-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione in several steps.

IT **282522-93-4P**, (5R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione **282522-94-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic amines for treating fibromyalgia and chronic fatigue syndrome)

RN 282522-93-4 CAPLUS

CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:475525 CAPLUS
DOCUMENT NUMBER: 133:109946
TITLE: Methylaminodihydroimidazoquinolinones for treating sexual disturbances and inducing mating in animals
INVENTOR(S): Meglasson, Martin Durham; McCall, Robert B.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000040226	A2	20000713	WO 1999-US27951	19991220
WO 2000040226	A3	20010201		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6455564	B1	20020924	US 1999-465668	19991217
BR 9916759	A	20010925	BR 1999-16759	19991220
EP 1140092	A2	20011010	EP 1999-967142	19991220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534376	T2	20021015	JP 2000-591983	19991220
NZ 512820	A	20021220	NZ 1999-512820	19991220
ZA 2001004283	A	20020524	ZA 2001-4283	20010524
US 2002107247	A1	20020808	US 2002-78611	20020219
US 2002198187	A1	20021226	US 2002-208353	20020730
US 2003004152	A1	20030102	US 2002-208084	20020730
US 2003013710	A1	20030116	US 2002-208644	20020730

PRIORITY APPLN. INFO.:

US 1999-114840P P 19990106
US 1999-115051P P 19990108
US 1999-115922P P 19990114
US 1999-120543P P 19990217
US 1999-465668 A3 19991217
WO 1999-US27951 W 19991220
US 2002-78611 A3 20020219

OTHER SOURCE(S): MARPAT 133:109946

GI



I

AB The present invention is a method of treating sexual disturbances in humans and inducing mating in non-human mammals using the compds. of formula (I: R1,R2,R3 = H, alkyl, alkenyl, cycloalkyl, etc.; X = H, alkyl, halogen, OH, etc.; A,B,D = CH, CH2, CO, N, etc.; n = 0 or 1) in a dosage range where the sexually therapeutic amt. is from about 0.2 through 8 mg/person/dose and where the sexually mating amt. is from about 0.003 through 0.2 mg/kg/dose.

IT **282522-93-4P 282522-94-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(treating sexual disturbances and inducing mating in animals)

RN 282522-93-4 CAPLUS

CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282522-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4
CMF C11 H13 N3 S

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 10:42:18 ON 21 JAN 2004)

FILE 'REGISTRY' ENTERED AT 10:42:32 ON 21 JAN 2004
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 20 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:43:22 ON 21 JAN 2004

10/634,355

L4 10 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

PALM INTRANET

Day : Wednesday
Date: 1/21/2004
Time: 11:52:10

Inventor Name Search Result

Your Search was:

Last Name = ACKER
First Name = BRAD

Application#	Patent#	Status	Date Filed	Title
60423155	Not Issued	020	11/01/2002	COMPOUNDS HAVING BOTH ALPHA7 NICOTINIC A ANTAGONIST ACTIVITY FOR THE TREATMENT OF
60400339	Not Issued	159	08/01/2002	1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC C(OF DISEASE
60382685	Not Issued	159	05/23/2002	BIS-ARYLSULFONES
60358205	Not Issued	159	02/20/2002	SUBSTITUTED-ARYL COMPOUNDS FOR TREATMEI
60358146	Not Issued	159	02/20/2002	AZABICYCLIC-CARBOXAMIDE COMPOUNDS FOR T
60357926	Not Issued	159	02/19/2002	AZABICYCLIC COMPOUNDS FOR THE TREATMENT
60357472	Not Issued	159	02/15/2002	SUBSTITUTED-ARYL COMPOUNDS FOR TREATMEI
60345075	Not Issued	159	11/09/2001	AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC C(DISEASE
60344905	Not Issued	159	12/21/2001	AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC C(OF DISEASE
60344436	Not Issued	159	10/26/2001	N-(1-AZABICYCLO MOIETIES)-SUBSTITUTED HETE COMPOUNDS FOR THE TREATMENT OF DISEASE
60342674	Not Issued	159	12/21/2001	N-(AZABICYCLO MOIETIES)-SUBSTITUTED HETER COMPOUNDS FOR THE TREATMENT OF DISEASE
60336977	Not Issued	159	11/08/2001	1-AZABICYCLIC-SUBSTITUTED HETEROARYL COM DISEASE
60334886	Not Issued	159	11/15/2001	1-AZABICYCLIC-SUBSTITUTED FUSED-HETEROAR TREATMENT OF DISEASE
60326565	Not Issued	159	10/02/2001	1-AZABICYCLIC [3.2.1]-SUBSTITUTED FUSED-HETE TREATMENT OF DISEASE
60301964	Not Issued	159	06/29/2001	SUBSTITUTED AZEPINO[4,5B]INDOLE DERIVATIVE
60266047	Not	159	02/01/2001	SUBSTITUTED 1, 2, 3, 4, 5, 6-HEXAHYDROAZEPINO[

	Issued			
60240005	Not Issued	159	10/13/2000	SILICA BASED LIGHT WEIGHT EUVL STAGES
60234376	Not Issued	159	09/20/2000	SUBSTITUTED 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5
60234101	Not Issued	159	09/21/2000	(5R0-5-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZ(
60199954	Not Issued	159	04/27/2000	(5R)-5-(MENTHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZ
60130811	Not Issued	159	04/23/1999	TETRACYCLIC AZEPINOINDOLE COMPOUNDS
60013805	Not Issued	159	03/21/1996	HIGH SPEED VIDEO DISTRIBUTION AND MANUFA(
10634355	Not Issued	030	08/05/2003	(5R)-5-(METHYAMINO)-5, 6-DIHYDRO-4H-IMIDAZO
10627140	Not Issued	020	07/25/2003	1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC C(OF DISEASE
10437478	Not Issued	020	05/14/2003	BIS-ARYLSULFONES
10394676	Not Issued	061	03/20/2003	SUBSTITUTED AZEPINO[4,5B]INDOLINE DERIVATI
10393968	Not Issued	041	03/20/2003	SUBSTITUTED AZEPINO[4,5B]INDOLE DERIVATIVE
10366894	Not Issued	030	02/14/2003	AZABICYCLIC COMPOUNDS FOR THE TREATMENT
10366855	Not Issued	030	02/14/2003	FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC TREATMENT OF DISEASE
10366431	Not Issued	041	02/13/2003	AZABICYCLIC COMPOUNDS FOR THE TREATMENT
10361705	Not Issued	020	02/10/2003	SUBSTITUTED-ARYL COMPOUNDS FOR TREATME
10288863	Not Issued	030	11/06/2002	AZABICYCLIC-SUBSTITUTED-HETEROARYL COMP DISEASE
10286177	Not Issued	030	11/01/2002	AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC C(DISEASE
10272802	Not Issued	041	10/17/2002	N-(AZABICYCLO MOIETIES)-SUBSTITUTED HETER COMPOUNDS FOR THE TREATMENT OF DISEASE
10262257	Not Issued	041	10/01/2002	AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYI TREATMENT OF DISEASE
10174203	Not Issued	083	06/17/2002	TETRACYCLIC AZEPINOINDOLE COMPOUNDS
09957625	6583135	150	09/20/2001	SUBSTITUTED AZEPINO[4,5B]INDOLE DERIVATIVE

09957319	6586421	150	09/20/2001	SUBSTITUTED AZEPINO[4,5B] INDOLINE DERIVATI
09943466	6542224	150	08/30/2001	SILICA-BASED LIGHT-WEIGHT EUV LITHOGRAPHY
09844947	Not Issued	071	04/27/2001	METHOD FOR PRODUCING TITANIA-DOPED FUSEI
09838054	Not Issued	161	04/19/2001	(5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO[4
09792852	6484711	150	02/23/2001	AUTOMATIC DEPTH OF CUT CONTROL FOR CONCI
09553246	6407092	150	04/20/2000	TETRACYCLIC AZEPINOINDOLE COMPOUNDS

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Acker **First Name** Brad

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page